As global markets navigate a mixed start to the new year, with U.S. stocks experiencing both gains and declines and notable economic indicators like the Chicago PMI showing contraction, investors are keenly observing opportunities for value amidst volatility. In such an environment, identifying undervalued stocks can be particularly appealing as these equities may offer potential for growth when broader market conditions stabilize or improve.
Name | Current Price | Fair Value (Est) | Discount (Est) |
Avant Group (TSE:3836) | ¥1878.00 | ¥3755.66 | 50% |
NBTM New Materials Group (SHSE:600114) | CN¥15.55 | CN¥31.07 | 49.9% |
Gaming Realms (AIM:GMR) | £0.36 | £0.72 | 49.9% |
Sudarshan Chemical Industries (BSE:506655) | ₹1120.30 | ₹2232.36 | 49.8% |
Kinaxis (TSX:KXS) | CA$170.99 | CA$340.11 | 49.7% |
ReadyTech Holdings (ASX:RDY) | A$3.15 | A$6.30 | 50% |
Vogo (ENXTPA:ALVGO) | €2.94 | €5.87 | 49.9% |
Exosens (ENXTPA:EXENS) | €22.505 | €44.77 | 49.7% |
iFLYTEKLTD (SZSE:002230) | CN¥45.41 | CN¥90.65 | 49.9% |
Salmones Camanchaca (SNSE:SALMOCAM) | CLP2434.90 | CLP4848.26 | 49.8% |
Click here to see the full list of 885 stocks from our Undervalued Stocks Based On Cash Flows screener.
Let's dive into some prime choices out of the screener.
Overview: CellaVision AB (publ) develops and sells instruments, software, and reagents for blood and body fluids analysis in Sweden and internationally, with a market cap of SEK4.93 billion.
Operations: The company's revenue is primarily derived from automated microscopy systems and reagents in the field of hematology, totaling SEK737.16 million.
Estimated Discount To Fair Value: 39.3%
CellaVision AB is trading at SEK 206.5, significantly below its estimated fair value of SEK 340.38, indicating substantial undervaluation based on cash flows. The company reported strong earnings growth of 33.9% over the past year and forecasts suggest continued robust earnings growth at 22.5% annually, outpacing the Swedish market's average growth rate. Recent financial results show increased revenues and net income for Q3 and nine months ending September 2024, reinforcing its positive cash flow outlook.
Overview: Digital China Holdings Limited is an investment holding company that offers big data products and solutions to government and enterprise customers mainly in Mainland China, with a market capitalization of approximately HK$5.20 billion.
Operations: The company's revenue is derived from three main segments: Big Data Products and Solutions (CN¥3.39 billion), Software and Operating Services (CN¥5.31 billion), and Traditional and Localization Services (CN¥10.03 billion).
Estimated Discount To Fair Value: 46.2%
Digital China Holdings is trading at HK$3.11, significantly below its estimated fair value of HK$5.78, highlighting potential undervaluation based on cash flows. The company is projected to achieve profitability within three years, with revenue growth forecasted at 8.8% annually—outpacing the Hong Kong market's average rate of 7.5%. Despite a low future return on equity of 7.6%, Digital China presents good relative value compared to peers and industry standards.
Overview: Pruksa Holding Public Company Limited, with a market cap of THB15.76 billion, operates through its subsidiaries to develop and sell residential real estate properties in Thailand.
Operations: The company's revenue segments include SBU Hospital with THB2.32 billion, SBU Townhouse with THB6.32 billion, SBU Condominium with THB5.74 billion, and SBU Single House with THB6.43 billion.
Estimated Discount To Fair Value: 11.4%
Pruksa Holding, trading at THB7.2, is slightly undervalued compared to its fair value of THB8.13 based on cash flows. Earnings are expected to grow significantly at 28.4% annually, surpassing the Thai market's average growth rate of 16.6%. However, profit margins have declined from 11.3% last year to 4.3%, and the dividend yield of 11.11% is not well covered by earnings, indicating potential risks despite promising revenue growth forecasts of 8.9%.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include OM:CEVI SEHK:861 and SET:PSH.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。